Search results for "AGENTS"

showing 10 items of 7330 documents

Fungal Necrotizing Scleritis After Intravitreal Injection Therapy

2020

PURPOSE To report a case of infectious necrotizing scleritis secondary to Aspergillus terreus after intravitreal injection therapy. METHODS This is a case report with literature review. RESULTS A 98-year-old woman receiving intravitreal aflibercept injections for neovascular age-related macular degeneration in the left eye presented with severe pain, redness, and purulent discharge at the injection site. She was initially treated with topical fortified antibiotics, and clinical improvement was achieved, although microbial cultures showed negative results. Two months later, she presented with severe ocular pain and was diagnosed with anterior necrotizing scleritis. Scleral scrapings were col…

medicine.medical_specialtyAntifungal Agentsmedicine.drug_classRecombinant Fusion ProteinsAntibioticsAngiogenesis InhibitorsmedicineAspergillosisHumansAspergillus terreusNecrotizing scleritisAfliberceptAged 80 and overVoriconazolebiologybusiness.industryInjection therapyMacular degenerationmedicine.diseasebiology.organism_classificationSurgeryOphthalmologyAspergillusReceptors Vascular Endothelial Growth FactorAcute DiseaseIntravitreal InjectionsWet Macular DegenerationEtiologyFemalebusinessEye Infections FungalScleraScleritismedicine.drugCornea
researchProduct

Steroid Receptor Expression in Endometria from Women Treated with Tamoxifen

1998

Abstract Breast cancer patients receiving tamoxifen (Tam) are at an increased risk for developing endometrial carcinomas, possibly due to the partial estrogenic effect of Tam on endometrial cells. Progestational therapy has not routinely been included in Tam regimens. It was our aim to determine the presence of estrogen receptors (ERs) and progesterone receptors (PRs) in normal and abnormal endometria from postmenopausal women with breast cancer who were treated with Tam. Standard immunohistochemical staining of ERs and PRs was performed on paraffin sections from formalin-fixed uterine curettings or hysterectomy specimens from 40 patients who had received 20–40 mg of Tam daily for a minimum…

medicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classReceptor expressionEstrogen receptorBreast NeoplasmsEndometriumEndometriumBreast cancerInternal medicineEndometrial PolypHumansMedicineRetrospective Studiesbusiness.industryObstetrics and Gynecologymedicine.diseasePostmenopauseTamoxifenmedicine.anatomical_structureEndocrinologyReceptors EstrogenOncologyEstrogenAdenocarcinomaFemaleReceptors ProgesteronebusinessTamoxifenmedicine.drugGynecologic Oncology
researchProduct

The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program o…

2013

BACKGROUND Compliance and persistence are often overlooked in adjuvant breast cancer treatment. PATIENTS AND METHODS PACT was a prospective, multicenter, randomized, open, parallel-group study assessing whether educational materials (EMs) enhanced compliance with aromatase inhibitor (AI) therapy in postmenopausal women with early, hormone-receptor-positive (HR+) breast cancer. The primary end points were compliance (proportion taking ≥ 80% anastrozole) at 12 months and persistence (proportion reporting anastrozole intake during the study period). RESULTS Four thousand eight hundred and forty-four patients were randomly assigned 1:1 to receive standard therapy or standard therapy with EMs. T…

medicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classmedicine.medical_treatmentAnastrozoleBreast NeoplasmsAnastrozolePactPersistence (computer science)Medication AdherenceEosinophilia–myalgia syndromeBreast cancerInternal medicineNitrilesmedicineHumansProspective StudiesEarly Detection of CancerAgedGynecologyAromatase inhibitorbusiness.industrySurrogate endpointHematologyMiddle AgedTriazolesmedicine.diseasePostmenopauseOncologyPatient ComplianceFemalebusinessAdjuvantmedicine.drugFollow-Up StudiesAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Pentaerithrityl tetranitrate improves angiotensin II induced vascular dysfunction via induction of heme oxygenase-1

2010

The organic nitrate pentaerythritol tetranitrate is devoid of nitrate tolerance, which has been attributed to the induction of the antioxidant enzyme heme oxygenase (HO)-1. With the present study, we tested whether chronic treatment with pentaerythritol tetranitrate can improve angiotensin II–induced vascular oxidative stress and dysfunction. In contrast to isosorbide-5 mononitrate (75 mg/kg per day for 7 days), treatment with pentaerythritol tetranitrate (15 mg/kg per day for 7 days) improved the impaired endothelial and smooth muscle function and normalized vascular and cardiac reactive oxygen species production (mitochondria, NADPH oxidase activity, and uncoupled endothelial NO synthase)…

medicine.medical_specialtyAntioxidantNitric Oxide Synthase Type IIImedicine.medical_treatmentVasodilator AgentsBlotting WesternFluorescent Antibody TechniquePentaerythritol tetranitratemedicine.disease_causePentaerythritolArticlechemistry.chemical_compoundInternal medicineRats Inbred SHRInternal MedicinemedicineAnimalsPentaerythritol TetranitrateEndothelial dysfunctionchemistry.chemical_classificationReactive oxygen speciesAnalysis of VarianceAngiotensin IImedicine.diseaseAngiotensin IIMitochondriaRatsHeme oxygenaseOxidative StressEndocrinologychemistryHeminEndothelium VascularReactive Oxygen SpeciesOxidative stressHeme Oxygenase-1
researchProduct

Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects

2019

Abstract There is no doubt about the relationship between LDL-C and cardiovascular risk, as well as about the benefits of statin treatment. Once the objective of LDL-C has been achieved, the evidences that demonstrate the persistence of a high cardiovascular risk, a concept called residual risk, are notable. The residual risk of lipid origin is based on atherogenic dyslipidemia, characterised by an increase in triglycerides and triglyceride-rich lipoproteins, a decrease in HDL-C and qualitative alterations in LDL particles. The most commonly used measures to identify this dyslipidemia are based on the determination of total cholesterol, triglycerides, HDL, non-HDL cholesterol and remaining …

medicine.medical_specialtyApolipoprotein BPhysical exercisechemistry.chemical_compoundFenofibrateRisk FactorsWeight lossInternal medicinemedicineHumansTriglyceridesDyslipidemiasHypolipidemic AgentsGeneral Environmental ScienceFenofibratebiologybusiness.industryCholesterolGeneral Engineeringnutritional and metabolic diseasesAtherosclerosismedicine.diseaseLipidsResidual riskCholesterolEndocrinologychemistryCardiovascular Diseasesbiology.proteinGeneral Earth and Planetary Scienceslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorsmedicine.symptombusinessDyslipidemiamedicine.drugLipoproteinClínica e Investigación en Arteriosclerosis (English Edition)
researchProduct

How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL

2017

Background and aims: The maintenance of clinically recommended levels of low-density lipoprotein cholesterol (LDL-C) through a statin therapy is a gold standard in the management of patients with dyslipidaemia and cardiovascular disease (CVD). However, even when LDL-C levels are at or below clinically recommended target levels, residual cardiovascular (CV) risk still remains. Therefore, assessing lipoproteins beyond LDL-C in managing CV risk is imperative. Methods: A working group of clinical experts have assessed the role of lipoproteins other than LDL-C in identifying the CV risk in patients with dyslipidaemia and CVD and in the management of atherogenic dyslipidaemia associated with a nu…

medicine.medical_specialtyApolipoprotein BType 2 diabetes030204 cardiovascular system & hematologyRisk AssessmentTriglyceride03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHigh-density lipoprotein cholesterolRisk FactorsInternal medicinemedicineInternal MedicineHumans030212 general & internal medicineAtherogenic dyslipidaemiaHypolipidemic AgentsbiologyCholesterolbusiness.industryDisease Managementnutritional and metabolic diseasesGeneral MedicineLipoprotein(a)Cholesterol LDLmedicine.diseaseCardiovascular diseaseCardiovascular riskResidual riskNon-high-density lipoprotein cholesterolEndocrinologychemistryCardiovascular DiseasesPractice Guidelines as Topicbiology.proteinlipids (amino acids peptides and proteins)Metabolic syndromeHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessRisk assessmentCardiology and Cardiovascular MedicineApolipoprotein BBiomarkersLipoproteinLipoprotein(a)
researchProduct

Future perspectives of the pharmacological management of diabetic dyslipidemia

2019

Introduction: Diabetic dyslipidemia is frequent among patients with type 2 diabetes mellitus (T2DM) and is characterized by an increase in triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), and small-dense (atherogenic) particles, and by a decrease in low high-density lipoprotein cholesterol (HDL-C) and apolipoprotein (Apo) A1 that are strongly related to insulin resistance. The increased flux of free fatty acids from adipose tissue to the liver aggravates hepatic insulin resistance and promotes all of aspects of the dyslipidemic state. Areas covered: Statins are the first-line agents for treatment while other lipid-lowering drugs (ezetimibe, fibrate and proprotein convertase…

medicine.medical_specialtyApolipoprotein Bmedicine.drug_classglucagon like peptide-1 receptor agonist (GLP-1RA)Fibrate030226 pharmacology & pharmacystatins03 medical and health sciences0302 clinical medicineInsulin resistanceEzetimibeInternal medicinemedicineHumansHypoglycemic AgentsPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsOmega 3 fatty acidDyslipidemiasHypolipidemic Agentsfibratebiologybusiness.industrydyslipidemianutritional and metabolic diseasesType 2 Diabetes MellitusGeneral MedicineLipidmedicine.diseasesodium/glucose cotransporter 2 inhibitors (SGLT-2is)LipidsEndocrinologyDiabetes Mellitus Type 2Cardiovascular Diseases030220 oncology & carcinogenesisDipeptidyl peptidase-4 inhibitors (DPP-4is)Dietary Supplementsbiology.proteinKexinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistancebusinessDyslipidemiamedicine.drugezetimibeproprotein convertase subtilisin/kexin type 9 (PCSK9)
researchProduct

2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardio…

2013

1. INTRODUCTION1.1 PrinciplesThe 2013 European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines continue to adhere to some fundamental principles that inspired the 2003 and 2007 guidelines, namely to base recommendations on properly conducted studies identified from an ext

medicine.medical_specialtyArterieKidney DiseasePrognosiPhysiologyCardiologyBlood PressureGuidelineRisk AssessmentDevice therapyRisk FactorsInternal medicineAntihypertensive treatmentInternal MedicineMedicineHumansIntensive care medicineLife StyleAntihypertensive Agentsbusiness.industryTask forceRisk FactorCardiovascular complicationOrgan damageArteriesCardiovascular riskLifestylePrognosisOrgan damageDevice therapyAntihypertensive AgentBlood pressureHypertensionCardiologyKidney DiseasesbusinessCardiology and Cardiovascular MedicineHumanJournal of hypertension
researchProduct

Non-glycemic effects of pioglitazone and incretin-based therapies.

2013

Atherosclerosis and cardiovascular events are highly prevalent and represent the major cause of mortality in patients with type 2 diabetes. Therefore, there is significant interest in the non-glycemic properties of anti-diabetic agents, particularly on those that are effective on cardiovascular risk factors. Thiazolidinediones and incretin-based therapies (IBTs) represent some of the most recent treatment options approved for the management of type 2 diabetes; these agents have shown important glycemic effects, as well as a number of non-glycemic effects. The latter include those on body weight, inflammation, hypertension and dyslipidemia, thus impacting the different components of the meta…

medicine.medical_specialtyAtherosclerosis cardiovascular events type 2 diabetes pioglitazone incretin-based therapiesClinical BiochemistryMEDLINEIncretinType 2 diabetesPharmacologyIncretinsDrug DiscoverymedicineHumansHypoglycemic AgentsIn patientIntensive care medicineGlycemicDyslipidemiasPharmacologyPioglitazonebusiness.industryBody Weightmedicine.diseaseCardiovascular DiseasesMolecular MedicineThiazolidinedionesMetabolic syndromebusinessPioglitazoneDyslipidemiamedicine.drug
researchProduct

Postoperative maintenance therapy for inflammatory bowel disease.

2006

. Curr Opin Gastroenterol. 2006 Jul;22(4):377-81. Postoperative maintenance therapy for inflammatory bowel disease. Cottone M, Orlando A, Modesto I. Department of General Medicine, Pneumology and Nutrition Clinic, Palermo University, Palermo, Italy. PURPOSE OF REVIEW: This review will highlight the knowledge gained from studies published in the year 2005 on maintenance treatment after surgery for inflammatory bowel diseases. RECENT FINDINGS: In Crohn's disease the role of smoking in increasing the risk of relapse and recurrence after surgery is confirmed. Ornidazole seems effective in reducing endoscopic recurrence and clinical relapse after surgery. Probiotics do not appear to be effective…

medicine.medical_specialtyAzathioprineInflammatory bowel diseaseEnteral NutritionMaintenance therapymedicineHumansIntensive care medicineDigestive System Surgical Procedurescrohn.post-operative.Postoperative CareCrohn's diseasebusiness.industryProbioticsGastroenterologyRetrospective cohort studyPouchitismedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisSurgeryAnti-Bacterial AgentsParenteral nutritionTreatment OutcomebusinessImmunosuppressive Agentsmedicine.drugCurrent opinion in gastroenterology
researchProduct